Bipolar Disorder, Depression
Conditions
Brief summary
This is a subject blind, investigator and sponsor open, randomized study consisting of 2 parts. Up to 15 healthy subjects will be included in the study. In the first part of the study the test retest reliability of the radiotracer \[11C\] PF 04767135 binding in man will be assessed. In the second part of this study, using \[11C\] PF 04767135, kappa opioid receptor occupancy (RO) will be assessed in up to three cohorts of subjects.
Interventions
DRUGPF-04455242
Single dose of up to 30 mg PF-04455242, delivered in capsule.
Sponsors
Pfizer
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy male and/or female subjects of non-childbearing potential between the ages of 18 and 55 years, inclusive. (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG and clinical laboratory tests.)
Exclusion criteria
* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). * Any condition possibly affecting drug absorption (eg, gastrectomy). * A positive urine drug screen at Screening or Day 0. * History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for men. * Use of tobacco- or nicotine-containing products within 3 months of screening. * Treatment with an investigational drug within 30 days or 5 half lives preceding the first dose of study medication (excluding \[11C\]PF 04767135). * 12 lead ECG demonstrating QTc \>450 msec at Screening. * Pregnant or nursing females; females of childbearing potential.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall kappa opioid receptor occupancy of PF 04455242. | Study Day 1 and 2 |
Secondary
| Measure | Time frame |
|---|---|
| Binding potential (BP) of [11C] PF 04767135. | Study Day 1 and 2 |
| Kappa opioid receptor occupancy of PF 04455242 at regions of interest in man. | Study Day 1 and 2 |
| Relationship between plasma PF 04455242 concentration and kappa opioid receptor occupancy (IC50). | Study Day 1 and 2 |
Countries
United States
Outcome results
None listed